Ravi Paluri to Aged, 80 and over
This is a "connection" page, showing publications Ravi Paluri has written about Aged, 80 and over.
Connection Strength
0.158
-
Paluri RK, Morgan CJ, Mooney DJ, Mgbemena O, Yang ES, Wei S, Kouba E, Naik G, El Mouallem NR, Poston T, Jones B, Nix J, Bolger GB, Deshazo M, Sonpavde G. Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder. Clin Genitourin Cancer. 2015 Oct; 13(5):469-75.
Score: 0.071
-
Williams GR, Al-Obaidi M, Dai C, Mir N, Challa SA, Daniel M, Patel H, Barlow B, Young-Smith C, Gbolahan O, Paluri R, Bhatia S, Giri S. Association of malnutrition with geriatric assessment impairments and health-related quality of life among older adults with gastrointestinal malignancies. Cancer. 2020 12 01; 126(23):5147-5155.
Score: 0.026
-
Tsongalis GJ, Al Turkmani MR, Suriawinata M, Babcock MJ, Mitchell K, Ding Y, Scicchitano L, Tira A, Buckingham L, Atkinson S, Lax A, Aisner DL, Davies KD, Wood HN, O'Neill SS, Levine EA, Sequeira J, Harada S, DeFrank G, Paluri R, Tan BA, Colabella H, Snead C, Cruz-Correa M, Ramirez V, Rojas A, Huang H, Mackinnon AC, Garcia FU, Cavone SM, Elfahal M, Abel G, Vasef MA, Judd A, Linder MW, Alkhateeb K, Skinner WL, Boccia R, Patel K. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer. Am J Clin Pathol. 2020 07 07; 154(2):266-276.
Score: 0.026
-
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer. 2016 08; 14(4):331-40.
Score: 0.018
-
Peker D, Parekh V, Paluri R, Deal T, Borate U, Di Stasi A, Harada S, Arroyo EA, Reddy V. Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience. Int J Hematol. 2014 Nov; 100(5):457-63.
Score: 0.017